Newsfiscal.ai
EyePoint Pharmaceuticals to Cut 53% of Workforce After Eye Disease Drug Trial Setback
· Published
Article summary
Following the failure of its LUCIA Phase 3 trial, EyePoint Pharmaceuticals announced a workforce reduction of 53%.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…